Articular mobility in systemic lupus erythematosus (SLE).

Area of Science:

• Rheumatology
• Immunology
• Clinical Medicine

Background:

• Inflammatory polyarthritis and corticosteroid use are anecdotally suggested to increase articular mobility.
• Systemic lupus erythematosus (SLE) is an autoimmune disease often associated with polyarthritis and treated with corticosteroids.
• Understanding factors influencing joint mobility in SLE is crucial for patient management.

Purpose of the Study:

• To investigate whether patients with systemic lupus erythematosus (SLE) exhibit increased articular mobility.
• To determine if corticosteroid therapy is associated with enhanced joint mobility in SLE patients.
• To explore the relationship between articular mobility, disease duration, and deformity in SLE.

Main Methods:

• A case-control study involving 90 female patients with SLE and 90 matched controls.
• Patients with SLE had polyarthritis and a history of corticosteroid therapy.
• Assessment of articular mobility using standardized scoring and comparison between groups.

Main Results:

• No significant difference in the prevalence of hypermobility between SLE patients (7%) and controls (6%).
• Pooled mobility and hand scores did not differ significantly between the SLE group and controls.
• No significant association found between articular mobility and age at onset, disease duration, or corticosteroid therapy.

Conclusions:

• Systemic lupus erythematosus (SLE) does not predispose individuals to a hypermobile tendency.
• Corticosteroid therapy in SLE patients does not appear to increase articular mobility.
• While deformity is associated with disease duration in SLE, it is not linked to articular mobility.